

Figure 1: Treatment options for newly diagnosed and hormone-sensitive prostate cancer





Figure 2: Treatment options and comparators evaluated in the Assessment Report



Comparison	Label	Studies
Docetaxel + ADT vs. ADT	1	GETUG-AFU 15; CHAARTED, STAMPEDE
Abiraterone + ADT vs. ADT	2	STAMPEDE, LATITUDE
Enzalutamide + ADT vs. ADT	3	ENZAMET, ARCHES
Apalutamide + ADT vs. ADT	4	TITAN
Abiraterone + ADT vs. Docetaxel + ADT	5	STAMPEDE
Enzalutamide + ADT vs. Docetaxel + ADT	6	-
Apalutamide + ADT vs. Docetaxel + ADT	7	-
Enzalutamide + ADT vs. Abiraterone + ADT	8	-
Apalutamide + ADT vs. Abiraterone + ADT	9	-
Apalutamide + ADT vs. Enzalutamide + ADT	10	-
Radiotherapy + ADT vs. ADT	11	STAMPEDE, HORRAD